IL-25 Induces Both Inflammation and Skin Barrier Dysfunction in Atopic Dermatitis
Mette Deleuran(Aarhus University Hospital), Christian Vestergaard(Aarhus University), Bent Deleuran(Aarhus University), Malene Hvid(Aarhus University), Gitte B. Christensen(Leo Pharma (Denmark)), Kaare Kemp(Leo Pharma (Denmark))
Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy
January 1, 2012
Cited by 57
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.5k
European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy
|Journal of the European Academy of Dermatology and Venereology|2022|419
Association of Family History of Autoimmune Diseases and Autism Spectrum Disorders
|PEDIATRICS|2009|409
Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder
|Journal of Investigative Dermatology|2016|377